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of patients who received MEL 200. Patients were matched for the
year of transplant, chemosensitivity, disease status at auto-HCT
and time from diagnosis to auto-HCT.
Results: Preparative regimens were MEL 140 (19 patients),
MEL180 (38 patients) and MEL 200 (253 patients). Patients in
MEL 140 groupwere older (median age 70), with 58%patients older
than 65 at auto-HCT (p 5 0.0001). Median serum creatinine level
(1.71 mg/dl) was higher in the MEL 140 group (p 5 0.007). There
was no significant difference in disease status (p 5 0.38) or chemo-
sensitivity (p5 0.28) between the 3 groups. Median times to neutro-
phil engraftment in MEL 140, 180 and 200 were 11, 10 and 10 days,
respectively (p5 0.15). Transplant-related mortality at 100 days was
0%, 2% and 0.8% in MEL 140, 180 and 200, respectively (p5 1.0).
Complete remission (CR) + very good partial remission (VGPR)
were seen in 42%, 37% and 45% in Mel 140, 180 and 200, respec-
tively (p 5 0.45). The overall response rate (CR + VGPR + PR)
was 89%, 71% and 82% in MEL 140, 180 and 200, respectively (p
5 0.54). Median follow up in surviving patients in Mel 140, 180
and 200 was 13.8, 24.3 and 18.3 months, respectively. There was
no significant difference in time to progression (p 5 0.27) between
Mel 140, 180 or 200. Kaplan-Meier estimates of 2-year progres-
sion-free survival were 69%, 72% and 52% (p 5 0.74), and 2-year
overall survival were 69%, 83% and 83% (p 5 0.48) in Mel 140,
180 and 200, respectively.
Conclusion: The dose of melphalan can be safely reduced to 140
mg/m2 in older patients or patients with renal insufficiency without
adversely impacting the response rate, duration of remission or
survival.471
AZTREONAM AND VANCOMYCIN USE FOR EPISODES OF FEBRILE
NEUTROPENIA DURING HEMATOPOETIC STEM CELL TRANSPLANTATION
Trifilio, S., Mehta, J. Feinberg School of Medicine, Northwestern Univer-
sity and Norhtwestern Memorial Hospital
The spectrum of bacterial infections seen during febrile neutro-
penia(FN) in HSCT recipients continues to change, especially
with the emergence of multi-drug resistant organisms. Aztreona-
m(AZ) plus Vancomycin (VAN) have been used successfully for
FN in cancer patients, however the effectiveness of AZ plus
VAN for FN during HSCT is largely unknown. A retrospective
chart review was performed to determine the effectiveness of AZ
in FN.
Methods: 822 consecutive HSCT patient charts were re-
viewed(2004-2008). All patients received a minimum of 48hours of
AZ/VAN treatment for FN. Patients had received ciprofloxacin as
prophylaxis. The criteria for success was based upon evidence based
guidelines for the evaluation of new anti-infective drugs in FN
FN(CID Vol.15 Nov 1992 Suppl: 206-15) as follows:
1. Unexplained fever: defervesence within 72hr without recurrence
and no clinical s/s infection.
2. Clinically defined infection: Clinical improvement including fe-
ver, without antibiotic change or death
3. Microbiologically defined infection: All s/s and microbiological
evidence of disease eradicated without recurrence for 7days.
Results: 67 AZ treated patients were identified. Demographics: age
5 59(24-77), gender male5 29, Diagnosis: myeloma5 48, NHL5
10, AML 5 7, HSCT type: autologous 5 45. allogeneic 5 22. Me-
dian time to start AZ(post-HSCT infusion): day +8(-6-12), Number
of AZ treatment days 5 6(2-33)
Treatment Outcome
1. Unexplained fever(n5 36): Success5 26/36(73%), 2 patients died
2. Clinically defined(n 5 12): Hospital Pneumonia(n 5 9): Success
5 5/9(55%-ATB changes), Typhlitis (n 5 1) 0/1 (ATB change),
Cellulitis(n 5 1)(0/1success (ATB change)
3. Microbiologically defined infection (see Table 1): 20 patients ex-
perienced 30 episodes of microbiologically confirmed infection.
The majority (80%) were gram positive cocci blood stream infec-
tions and were successfully treated (80%-2 died). Gram negative
BS infection overall success was 50%(1died)6 patients developed clinical CDAD and 9 patients became VRE
surveillance positive shortly after AZ treatment. A non-significant
trend towards more BS infections was seen in allo-HSCT recipi-
ents(p 5 0.086)
Conclusion: AZ/VAN was effective in preventing breakthrough in-
fections for patients with unexplained fever, but less effective for pa-
tients with documented infections, requiring change or addition of
antibiotics. These results are comparable to those seen in non-
HSCT cancer patients with FN(Bodey et al.Cancer 1996 Apr1
77(7)).
Table 1. Microbiologically Defined Infection
Organism Source Successful Outcome(%)Strept Viridans blood (n 5 11) 91 (1 died-polymicrobial)
CONS(2 positive cx’s at 2sites blood (n 5 5) 80 (changed atb)
Entereococcus Faecalis blood (n 5 4) 75 (1died-polymicrobial)
MSSA blood (n 5 2) 50 (1 died-polymicrobial
E.Coli blood 5 1/
urine 5 1
BS-1 died//Urine 5 successEnterobacter urine (n 5 1) 100
Burkholderia blood 5 1 0 ( died-polymicrobial)
C.Diff stool (n 5 3) 66 (1 died-polymicrobial)472
THE IMPACT OF PRE-TRANSPLANT VALGANCICLOVIR ON EARLY CYTO-
MEGALOVIRUS REACTIVATION AFTER ALLOGENEIC HEMATOPOIETIC
STEM CELL TRANSPLANT
Wilhelm, K., Gulbis, A., Maewal, I., Cool, R., Ferguson, J.,
Westmoreland, M., Martinez, C., Saliba, R., Rondon, G., Chemaly, R.,
Champlin, R., Kebriaei, P. The University of Texas MDAnderson Cancer
Center, Houston, TX
Background: Cytomegalovirus (CMV) reactivation is a common
complication of allogeneic hematopoietic stem cell transplant
(HSCT) occurring in up to 80% of seropositive patients. Progres-
sion to CMV disease occurs in less than 10% of patients but still car-
ries a significant risk of death. Either pre-emptive or prophylaxis
strategies are generally accepted as methods to prevent CMV dis-
ease. The use of pre-transplant ganciclovir during the conditioning
regimen followed by pre-emptive therapy has also been used in an at-
tempt to reduce the rate of early CMV reactivation, but strong data is
lacking. In this retrospective study, we evaluated the impact of pre-
transplant valganciclovir (VGC) during the conditioning regimen
followed by a pre-emptive approach on the rate of early CMV reac-
tivation after allogeneic HSCT.
Methods: This was a retrospective review of 272 patients who re-
ceived an allogeneic HSCT between 11/2008 and 1/2011. Prior to
July 2010, patients received VGC 900mg PO BID during the condi-
tioning regimen followed by a pre-emptive strategy. After July 2010,
VGC was eliminated from the pre-transplant regimen and the pre-
emptive strategy was employed alone. The no-VGCgroup was iden-
tified as consecutive patients transplanted after the change in prac-
tice. Matched controls were obtained from the 2 years prior to the
change in practice (VGC group). Controls were matched on the fol-
lowing characteristics: CMV serostatus of patient and donor, donor
type, disease, disease status, preparative regimen intensity, and age.
The primary objective was the rate of CMV reactivation through
day 100 following HSCT. CMV reactivation was defined as greater
than or equal to 3 cells by antigenemia.
Results: 136 patients in each group were evaluated. Baseline charac-
teristics were similar. The rate of CMV reactivation through day 100
was 41% in the no-VGC group compared to 46% in the VGC group
(p-value5 0.4). Median time to CMV reactivation was earlier in the
no-VGC group compared to the VGC group (26 vs 34 days; p 5
0.008). Day 100 survival (90% VGC vs 91% no-VGC; p-value 5
0.8) was similar between the groups.
Conclusion: Although the time to CMV reactivation is signifi-
cantly longer in patients who received VGC during the transplant
preparative regimen, this did not impact the rate of CMV reactiva-
tion or survival by day 100. Based on this data, this strategy is not
recommended. Newer strategies to reduce CMV reactivation are
needed.
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Ave
of E
Apre
erapy.p-valueAge, median 53 54 0.8
Active disease 69 (51%) 68 (50%) NR
Recipient/Donor CMV serostatus
R+/D+ 66 (48%) 68 (50%)
R-/D+ or R+/D- 66 (48%) 63 (46%)
R-/D- 4 (3%) 5 (4%) 0.5
Diagnosis
Acute Leukemia 96 (70%) 96 (70%)
Chronic Leukemia 18 (13%) 18 (13%)
Other 22 (17%) 22 (17%) NR
Regimn Intensity *†
Myeloablative 87 (64%) 95 (70%)
Reduced-Intensity 26 (19%) 21 (15%)
Non-Myeloablative 23 (17%) 20 (15%) 0.6
Donor Type
Matched related 55 (40%) 55 (40%)
Matched unrelated 72 (54%) 72 (54%)
1 Antigen mismatched unrelated 3 (2%) 3 (2%)
Haploidentical 5 (4%) 5 (4%) NR
CMV reactivation 56 (41%) 63 (46%) 0.4
Median days to CMV reactivation 26 (range 0-85) 34 (range 2-97) 0.008
CMV disease 1 (0.7%) 5 (4%) 0.1
Day 100 Survival 91% 90% 0.8*Pasquini MC, Wang Z. Current use and outcome of hematopoietic
stem cell transplantation: Part I CIBMTR summary slides, 2009. CIBMTR
Newsletter (serial online), 2009; (15)1:7-11.
†Bacigalupo A, et al. Defining the Intensity of Conditioning Regimens:
Working Definitions. Biol Blood Marrow Transplant 2009; 15: 1628-1633.
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EXTENDED USE OF APREPITANT IN PEDIATRIC PATIENTS
Williams, D.1, Rohatgi, R.1, Seaton, A.2, Makonnen, T.3 1Children’s
National Medical Center, Washington, DC; 2University of Maryland;
3Virginia Commonwealth University
Purpose:This will report a single center experience of safety and ef-
ficacy of aprepitant used for treatment of nausea and vomiting in pe-
diatric stem cell transplant patients, used for greater than 4 days.
Background: Aprepitant is a nuerokinin-1 receptor antagonist that is
FDAapproved topreventnausea andvomitingwithmoderate tohighly
emetogentic chemotherapy. Aprepitant is utlized in combination with
standard antiemtic therapy for a3daydosing schedule in adult patients.
This is a case series inwhichpediatric stemcell transplantpatientswere
prescribed aprepitant for the treatment of nausea and vomiting.
Methods: This is a retrospective review of patient charts and data.
Patients prescribed aprepitant fore extended dosing at Children’s
National Medical Center between the dates of January 1, 2009 and
December 31, 2010 were included.
Inclusion Criteria: Aprepitant prescription for greater than 4 days
Age between 1 year and 17.9 years at the initiation of aprepitant
therapy
Results: Six patient therapy encounters were observed. Patient ages
ranged from 2 years to 16 years of age at the time of therapy. The
duration of aprepitant usage ranged from 5 to 12 days. The doses
of aprepitant ranged from 45mg per body surface area daily to
70mg per body surface area daily. Five out of six (83%) patient en-
counters demonstrated an improvement of emesis with the additionrage Number
mesis During
pitant Therapy
0
0.16
1.6
0.16
0.22
0.25of aprepitant, both during aprepitant therapy and for 72 hours fol-
lowing the discontinuation of aprepitant. (See Table). The number
of rescue antiemetics required did not differ with the addition of
aprepitant. There were no adverse events attributed to aprepitant
usage.
Conclusion: In a single center experience, aprepitant therapy is effec-
tive at decreasing episodes of emesis during therapy and the time pe-
riod up to 72 hours after aprepitant discontinuation, in pediatric
stem cell transplant patients. Use of aprepitant therapy for greater
than three days is not associated with any significant adverse events.
Variations in patient age and standardized dosing based on body sur-
face area need to be further investigated and developed. Additional
larger studies are warranted to determine the most appropriate dosing
scheme based on pediatric developmental pharmacokinetic principles.
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DOSING OF BUSULFAN IN OVERWEIGHT AND OBESE PATIENTS
COMPARED TO NORMALWEIGHT PATIENTS UNDERGOING ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION (alloHSCT)
Tkacz Brown, V.1, Zahurak, M.2, Hatfield Seung, A.1, Rosner, G.2,
Jones, R.J.2, Luznik, L.2, Lombardi Thomas, L.1 1The Johns Hopkins
Hospital, Baltimore, MD; 2The Sidney Kimmel Comprehensive Cancer
Center at The Johns Hopkins Hospital and University, Baltimore, MD
Busulfan has a narrow therapeutic index, making dosing in obesity
a therapeutic dilemma. The busulfan pharmacokinetic (PK) profile is
related to many variables including body size. By normalizing dosing
tobody size, variability in clearance is reduced.The difficulty is the se-
lection of an appropriatemeasure of body size for normalization. The
objectives of this study were to determine if busulfan dosed on ideal
body weight (IBW) in overweight patients (BMI $ 25 kg/m2) leads
to differences in the PK parameter area under concentration-versus-
time curve (AUC) for the first dose and dosing adjustments compared
tonormalweight patients (BMI\25 kg/m2). Secondary objectives in-
clude comparison of transplant outcomes including sinusoidal ob-
struction syndrome (SOS), non-relapse mortality (NRM), event-free
survival (EFS), and overall survival (OS). A retrospective chart review
included 131 patients with hematologic malignancies, 69 of whom
were not in remission, who received an alloHSCT with our busul-
fan/cyclophosphamide preparative regimen and post-transplant cy-
clophosphamide alone as GVHD prophylaxis. Oral or intravenous
busulfan was administered to 72 and 59 patients, respectively, with
routine first dose PK assessment performed with a goal AUC/dose
of 800 – 1400 mMol-min/L. Themajority of the population was over-
weight (67%) and had similar characteristics, with the exception of
a higher portion of males in the overweight group (37% vs. 58%;
p 5 0.026). The median first dose busulfan AUC was 1153 mMol-
min/L (range: 659-1805 mMol-min/L) in the normal weight patients
and 915 mMol-min/L (range: 482-1875 mMol-min/L) in the over-
weight patients (p 5 0.0001); this did not translate into a difference
in dose adjustments at first assessment (p 5 0.522). Ten cases of
SOS were observed with a trend to higher incidence in the normal
weight patients (12% vs. 6%; p 5 0.30). The two year EFS and OS
were improved in overweight patients EFS: 35% (95% CI: 21, 49%)
vs 40% (95% CI: 30, 51%) and OS: 42% (95% CI: 27, 57%) vs
56% (95% CI: 44, 66%), but these differences were not significant
(EFS p5 0.37 and OS p5 0.26). Two year NRMwas lower in over-
weight patients NRM: 23% (95% CI: 12, 37%) vs 12% (95% CI: 6,
19%)p5 0.18.These results demonstrate thatwhenbusulfan is dosed
on IBW, overweight patients may have a lower initial busulfan AUC
than normal weight patients, but these pharmacokinetic differences
may not translate into differences in clinical outcomes.Average Number
of Emesis after
Aprepitant Therapy*
Aprepitant Daily
Dosage (mg/BSA) Patient Age (Years)
1 70 13
0.66 45 16
0 50 3
2 63 3
0 63 3
0 63 4
